Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Yael L. Maxwell

August 29, 2016

News Conference News ESC 2016

Another Meeting, Another Mesenchymal Stem Cell Study (or Two), With Mixed Results

Shelley Wood

August 28, 2016

News Daily News

Las Estatinas Minimizan pero No Eliminan el Exceso de Riesgo de Enfermedad Coronaria y Muerte en la Hipercolesterolemia Familiar

Todd Neale

July 12, 2016

News Daily News

美国和欧洲的心衰指南提倡使用两个新疗法

L.A. McKeown

May 24, 2016

News Daily News

US and European Heart Failure Guidelines Advocate Use of Two New Therapies

L.A. McKeown

May 24, 2016

News Industry News

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

October 27, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Daily News

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

Todd Neale

January 28, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

News Daily News

Cell Therapy Shows Promise for Limb Ischemia Due to PAD, Buerger’s Disease

Caitlin E. Cox

January 06, 2011

Advertisement

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Another Meeting, Another Mesenchymal Stem Cell Study (or Two), With Mixed Results

Las Estatinas Minimizan pero No Eliminan el Exceso de Riesgo de Enfermedad Coronaria y Muerte en la Hipercolesterolemia Familiar

美国和欧洲的心衰指南提倡使用两个新疗法

US and European Heart Failure Guidelines Advocate Use of Two New Therapies

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Cell Therapy Shows Promise for Limb Ischemia Due to PAD, Buerger’s Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content